MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech in a Minute: Stryker's Mako Deal Pays Off, a Coronavirus Battle Plan, and More

Stryker will be juicing its Mako robot for years to come and FDA gears up for the insanely contagious Coronavirus. But first, how is Intuitive Surgical handling increasingly noisy competition?

We know your time is precious so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.

Image by OpenClipart-Vectors on Pixabay

Robotic Competitors Pump up the Volume

The robotic surgery market is becoming increasingly noisy as new entrants move in and companies like Medtronic and Johnson and Johnson become more vocal about their plans in robotics. This means elongated price negoation timelines and delayed deals for Intuitive Surgical, but the market pioneer seems prepared to handle the extra noise.

 

We Imagine Stryker Laughing All the Way to the Bank

Back in 2013, analysts balked at the price Stryker paid to acquire Mako (a whopping $1.6 billion), but the company just reported its strongest robot quarter since launching the ever-popular robot. Globally, Stryker sold  89 Mako robots in Q4 (63 of which were U.S. sales) versus 54 in the comparable quarter a year ago.

Coronavirus Is Insanely Contagious, but FDA Has a Plan

It seems The entire world is concerned about the coronavirus, and for good reason. But have no fear U.S. readers, FDA is on the case. The agency has a strategy that will see it working with industry and international partners to diagnose, treat, mitigate, and prevent outbreaks.

Filed Under
500 characters remaining